Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
In 2023, the FDA designated BPC-157 as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmaceutical companies, and there is insufficient evidence regarding potential harm to humans
That said, peptide therapy is not for everyone
Prescription Requirements for Different B12 Formulations Prescription needs for B12 formulations vary by type and patient condition
No confirmed evidence from published studies demonstrates that BPC-157 causes cancer, though its angiogenic mechanism creates a theoretical risk of accelerating growth in pre-existing tumors through increased vascular supply
Chemotoxicity Rescue Chemotherapy (e.g., Doxorubicin) induces widespread cellular senescence
US$ 23.57
US$ 20.97
US$ 29.64
US$ 28.74
US$ 27.01
US$ 22.18
US$ 26.65
US$ 28.35
